ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The ASCO 2026 poster presentation highlighted the long-term results of a phase 1/1b study involving ficerafusp alfa combined with pembrolizumab for treating recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. The study demonstrated sustained depth and durability of response, showcasing the potential of this combination therapy.
Price reaction · baseline $21.75 (2026-05-29 close) · 2 other BCAX headline(s) in the window, move may be shared
day 0 close
-5.2%
day 1 · peak
-9.7%
day 3
-6.2%
Market Sentiment Analysis
POSITIVE FACTORS
Sustained depth of response reported.
Durability of response shows promise.
Long-term results from expansion cohorts are encouraging.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Ficerafusp alfa
Phase 2 · Squamous Cell Carcinoma of Head and Neck (SCCHN)
Full Press Release Details
The post ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab appeared first on Bicara Therapeutics .
Frequently Asked Questions
What was presented at ASCO 2026?
The ASCO 2026 presentation focused on long-term results of ficerafusp alfa with pembrolizumab.
What type of cancer was studied?
The study involved recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.
What were the key findings?
The findings highlighted sustained depth and durability of response from the treatment.